Zacks Investment Research·6d ago
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEXSYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
Stryker's accelerating revenue growth (9.4% in 2026Q2) and expanding gross margins (68.3%) underscore robust demand and operational leverage, yet the surge in goodwill to $25.3B (53% of total assets) and volatile cash conversion (OCF/NI swung from 0.26 to 3.54...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 9.4% in 2026Q2 with gross margin expanding to 68.3%, though net margin volatility (8.5% in 2024Q4 vs. 19.4% in 2026Q2) suggests one-time benefits.
Stryker Corporation has a wide moat, indicating strong competitive advantages and sustainable profitability in the medical devices sector.
The company benefits from consistent demand for medical procedures, supporting stable revenue growth.
Stryker's continued advancements in medical devices and robotics position it as a leader in healthcare technology.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $3.69+5.7% vs $3.49 | $6.6B+0.1% vs $6.6B |
Q2 2026 Apr 30, 2026 | $2.60-12.8% vs $2.98 | $6.0B-5.0% vs $6.3B |
Q1 2026 Jan 29, 2026 | $4.47+1.6% vs $4.40 | $7.2B+0.7% vs $7.1B |
Q4 2025 Oct 30, 2025 | $3.19+1.9% vs $3.13 | $6.1B+0.2% vs $6.0B |
SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists.
Investors looking for stocks in the Medical - Products sector might want to consider either GE HealthCare Technologies (GEHC) or Stryker (SYK). But which of these two stocks is more attractive to value investors?
New additions advance surgical planning, implant flexibility and connected care across Stryker's Foot & Ankle portfolio Stryker is launching Prophecy® Surgical Planning for the Incompass™ Total Ankle System and introducing Hoffmann®LRF smartHEX™ at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. Prophecy® Surgical Planning, which has supported patient-specific planning for more than 100,000 ankle cases over 14 years, is now available with the Incompass™ Total Ankle System, giving surgeons access to 3D visualization and both resect-through and pin-through fixation options within a single connected platform.
Benchmark SYK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Stryker Corporation (SYK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $275.07 | $105.45B | 32.75 | 11.16% | 12.92% | 15.08% | 1.22% | |
| $93.98 | $18.18B | 26.47 | 7.2% | 9.48% | 6.36% | — | |
| $44.92 | $66.77B | 23.15 | 19.87% | 17.47% | 14.76% | — | |
| $88.78 | $51.12B | 48.51 | 11.55% | 15.43% | 9.66% | — | |
| $183.00 | $50.42B | 31.39 | 8.23% | 4.52% | 3.79% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — |
Stryker Corporation (SYK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Stryker Corporation (SYK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 26, 2026·SEC
May 20, 2026·SEC
Get notified when SYK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Stryker Corporation (SYK) stock FAQ — growth, dividends, profitability & financials explained
Stryker Corporation (SYK) reported $25.84B in revenue for fiscal year 2025. This represents a 2739% increase from $910.1M in 1996.
Stryker Corporation (SYK) grew revenue by 11.2% over the past year. This is steady growth.
Yes, Stryker Corporation (SYK) is profitable, generating $3.73B in net income for fiscal year 2025 (12.9% net margin).
Yes, Stryker Corporation (SYK) pays a dividend with a yield of 1.22%. This makes it attractive for income-focused investors.
Stryker Corporation (SYK) has a return on equity (ROE) of 15.1%. This is reasonable for most industries.
Stryker Corporation (SYK) generated $4.70B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
